FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213420121> ?p ?o ?g. }

• W4213420121 abstract "This article investigated whether Runt-Related Transcription Factor 3 (RUNX3) and enhancer of zeste homolog 2 (EZH2) can be used to evaluate the clinical efficacy of neoadjuvant therapy and prognosis of locally advanced rectal cancer (LARC).Eighty LARC patients admitted to the Tianjin Medical University Cancer Institute/Hospital and First Affiliated Hospital of Hebei North University from Jan 2015 to Jan 2016 were enrolled. The patients were followed up for 60 months through hospital visits. All patients received neoadjuvant chemoradiotherapy (long range radiotherapy + oral capecitabine) + total mesorecta excision (TME) surgery. The clinical efficacy of the treatments was evaluated through endoscopic, radiography, and tumor regression grade (TRG). In addition, expression level of RUNX3 and EZH2 was quantified via immunohistochemistry. The association of RUNX3 and EZH2 with clinicopathological characteristics of advanced tumors and efficacy of neoadjuvant therapy was explored. Logistic regression analysis was performed to identify predictors of efficacy of neoadjuvant chemoradiotherapy. Survival curve was used to evaluate the impact of RUNX3 and EZH2 on the prognosis of LARC patients.A total of 80 patients diagnosed with LARC were enrolled in the study. Expression of RUNX3 was elevated in 25 (31.25%) patients, whereas expression of EZH2 was upregulated in 44 (55.00%) patients. Analysis of tumor regression identified 10 cases with TRG grade 0 (pathologic complete response, PCR), 24 cases with TRG grade 1, 35 cases with TRG grade 2, and 11 cases with TRG grade 3. Furthermore, 38 cases had significant down-staging, and 42 cases showed no significant down-staging as revealed by endoscopy and imaging. Patients with high expression of RUNX3 showed better tumor regression response and down-staging compared with those with low expression of RUNX3 (P < 0.001, P < 0.001). Moreover, patients with low EZH2 expression achieved TRG grade 0 and 1 response and down-staging effect compared with those with high expression of EZH2 (P < 0.001, P < 0.001). Logistic regression analysis showed that high expression of RUNX3, low expression of EZH2, and clinical N (cN) stage were good predictors of tumor regression response and down-staging. The 5-year disease free survival (DFS) and overall survival (OS) were 48.75 (39/80) and 58.75% (47/80), respectively. The 5-year DFS and OS of patients with high RUNX3 expression were significantly higher than low RUNX3 expression, whereas the 5-year DFS and OS of patients with high EZH2 expression were significantly lower than low EZH2 expression (P < 0.001). Univariate survival analysis showed that RUNX3 expression, EZH2 expression, cN, clinical T (cT), pathological T (pT) and pathological N (pN) were significantly correlated with the 5-year DFS and 5-year OS. Multivariate survival analysis showed that EZH2 expression and PN were good predictors of 5-year DFS and 5-year OS, whereas RUNX3 was a good predictor of 5-year DFS but not 5-year OS.Expression level of RUNX3 and EZH2 accurately predicts clinical efficacy of neoadjuvant chemoradiotherapy and the prognosis of LARC patients, suggesting that RUNX3 and EZH2 can be used as pivotal clinical predictors for LARC." @default.
• W4213420121 created "2022-02-25" @default.
• W4213420121 creator A5012014956 @default.
• W4213420121 creator A5020236787 @default.
• W4213420121 creator A5024225590 @default.
• W4213420121 creator A5052780403 @default.
• W4213420121 creator A5057444370 @default.
• W4213420121 creator A5057952053 @default.
• W4213420121 date "2022-02-24" @default.
• W4213420121 modified "2023-09-25" @default.
• W4213420121 title "Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer" @default.
• W4213420121 cites W2144717403 @default.
• W4213420121 cites W2560868131 @default.
• W4213420121 cites W2743609102 @default.
• W4213420121 cites W2757549725 @default.
• W4213420121 cites W2771199480 @default.
• W4213420121 cites W2804331259 @default.
• W4213420121 cites W2896353469 @default.
• W4213420121 cites W2955579119 @default.
• W4213420121 cites W2964995320 @default.
• W4213420121 cites W2987805875 @default.
• W4213420121 cites W2991559579 @default.
• W4213420121 cites W2996017286 @default.
• W4213420121 cites W2998954417 @default.
• W4213420121 cites W3008394279 @default.
• W4213420121 cites W3021172392 @default.
• W4213420121 cites W3039610753 @default.
• W4213420121 cites W3085716871 @default.
• W4213420121 cites W3093415007 @default.
• W4213420121 cites W3102782588 @default.
• W4213420121 cites W3106557774 @default.
• W4213420121 cites W3108101514 @default.
• W4213420121 cites W3109371411 @default.
• W4213420121 cites W3115906622 @default.
• W4213420121 cites W3118972631 @default.
• W4213420121 cites W3194731726 @default.
• W4213420121 cites W327384751 @default.
• W4213420121 doi "https://doi.org/10.3389/fonc.2022.713335" @default.
• W4213420121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35280723" @default.
• W4213420121 hasPublicationYear "2022" @default.
• W4213420121 type Work @default.
• W4213420121 citedByCount "0" @default.
• W4213420121 crossrefType "journal-article" @default.
• W4213420121 hasAuthorship W4213420121A5012014956 @default.
• W4213420121 hasAuthorship W4213420121A5020236787 @default.
• W4213420121 hasAuthorship W4213420121A5024225590 @default.
• W4213420121 hasAuthorship W4213420121A5052780403 @default.
• W4213420121 hasAuthorship W4213420121A5057444370 @default.
• W4213420121 hasAuthorship W4213420121A5057952053 @default.
• W4213420121 hasBestOaLocation W42134201211 @default.
• W4213420121 hasConcept C121608353 @default.
• W4213420121 hasConcept C126322002 @default.
• W4213420121 hasConcept C143998085 @default.
• W4213420121 hasConcept C151956035 @default.
• W4213420121 hasConcept C2777909004 @default.
• W4213420121 hasConcept C2778292576 @default.
• W4213420121 hasConcept C2778424827 @default.
• W4213420121 hasConcept C509974204 @default.
• W4213420121 hasConcept C526805850 @default.
• W4213420121 hasConcept C530470458 @default.
• W4213420121 hasConcept C71924100 @default.
• W4213420121 hasConcept C90924648 @default.
• W4213420121 hasConceptScore W4213420121C121608353 @default.
• W4213420121 hasConceptScore W4213420121C126322002 @default.
• W4213420121 hasConceptScore W4213420121C143998085 @default.
• W4213420121 hasConceptScore W4213420121C151956035 @default.
• W4213420121 hasConceptScore W4213420121C2777909004 @default.
• W4213420121 hasConceptScore W4213420121C2778292576 @default.
• W4213420121 hasConceptScore W4213420121C2778424827 @default.
• W4213420121 hasConceptScore W4213420121C509974204 @default.
• W4213420121 hasConceptScore W4213420121C526805850 @default.
• W4213420121 hasConceptScore W4213420121C530470458 @default.
• W4213420121 hasConceptScore W4213420121C71924100 @default.
• W4213420121 hasConceptScore W4213420121C90924648 @default.
• W4213420121 hasLocation W42134201211 @default.
• W4213420121 hasLocation W42134201212 @default.
• W4213420121 hasLocation W42134201213 @default.
• W4213420121 hasLocation W42134201214 @default.
• W4213420121 hasOpenAccess W4213420121 @default.
• W4213420121 hasPrimaryLocation W42134201211 @default.
• W4213420121 hasRelatedWork W1983052552 @default.
• W4213420121 hasRelatedWork W2002928668 @default.
• W4213420121 hasRelatedWork W2029040122 @default.
• W4213420121 hasRelatedWork W2107653012 @default.
• W4213420121 hasRelatedWork W2145753255 @default.
• W4213420121 hasRelatedWork W2386824526 @default.
• W4213420121 hasRelatedWork W2404042595 @default.
• W4213420121 hasRelatedWork W2404294814 @default.
• W4213420121 hasRelatedWork W2601851885 @default.
• W4213420121 hasRelatedWork W3090963952 @default.
• W4213420121 hasVolume "12" @default.
• W4213420121 isParatext "false" @default.
• W4213420121 isRetracted "false" @default.
• W4213420121 workType "article" @default.